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5 provided strong evidence to suggest that the cloned enzyme is the dominant HS-degrading enzyme in mammalian tissues and reinforced the notion that it represents a highly attractive drug target. Human HPSE is expressed as a 543 amino acid 65 kDa latent pro-enzyme and is proteolytically processed to produce an active enzyme that has been suggested to be a heterodimer composed of an 8 kDa and a 50 kDa polypeptide chain, derived from the N-terminal and C-terminal regions, respectively (11, 18, 20, 22) .
Structure-function analysis of the human enzyme has indicated it is a member of the clan A glycosyl hydrolase family, containing a structurally conserved TIM-barrel domain with a common catalytic mechanism that is dependent on two conserved acidic residues, a proton donor at E225 and a nucleophile at E343 (23) . A single gene located at chromosome 4q21.3 encodes HPSE (11, 24, 25) . Northern blot analysis has identified two major HPSE mRNA transcripts, a 1.7kb mRNA expressed only in immune tissues and placenta, and a 5 kb mRNA that shows similar distribution but is also expressed at low levels in most non-immune tissues (18, 26) .
The tight regulation of HPSE function is clearly of critical importance in ensuring homeostasis of the normal physiological processes in which it is involved. For example, T cells have been shown to secrete high levels of HPSE activity only upon activation when they are required to migrate to a site of inflammation (27) (28) (29) . A number of points of control of HPSE function are possible, including regulation at the transcriptional level, as well as in the translation, processing and activity of the enzyme. Advances have been made in understanding the processing of the proenzyme (11, 18, 20, 22) , and also the intracellular location and environment that influences its activity (30) (31) (32) . In contrast, little is known of the mechanisms that control HPSE gene transcription. Recently it was suggested that transcription factors of the Sp1 and ETS families play a role in controlling the basal activity of human HPSE gene expression (33, 34) . However, nothing is known about the mechanisms that may regulate inducible transcription of the HPSE gene. In this study we have shown that human HPSE transcription is induced upon activation of T cells. Furthermore, we have functionally analysed the HPSE promoter in T cells and identified the Cell Culture, Transfections and Luciferase assays-Jurkat T cells were cultured in RPMI medium supplemented with 10% Fetal Calf Serum in a humidified atmosphere of 5% CO 2 .
Transient transfections were performed using Bio-Rad Gene Pulser II at 270 Volts and 975 Capitance with 5 mg of reporter construct being transfected per 5 x 10 6 cells. For the co-transfection experiments a constant amount of total DNA was used, i.e, when decreasing amounts of pCB6-Egr1 were transfected, the balance was made up by using the backbone construct, pCB6+. After electroporation, cells were rested for 24 hours and then stimulated with 20 ng/ml of phorbol 12-myristate 13-acetate (PMA) (Sigma, St Louis, MO) and 1 mM Calcium Ionophore (IO) (Sigma, St Louis, MO). Cell lysates were harvested after 24 hours by three rounds of freeze/thawing and 40 mg of total protein was used for luciferase assays according to a previously published method (35) . Light emission was measured using a Packard Top Count Luminescence Counter.
Plasmid Constructs-Fragments of the human HPSE gene promoter (282 bp and 1399 bp)
were amplified by PCR from human genomic DNA that had been purified from blood using JetQuick construct containing a 509 bp promoter fragment. The Egr1 mutant construct, pXP-1/280bpMUT, was generated by splice overlap extension (SOE) PCR by mutating the core sequence of the putative Egr1 binding site GGCG motif to TTAT using the pXP-1/280bp construct as a template. Briefly two PCR reactions were performed to generate overlapping 5' and 3' fragments encoding each mutation, which were then spliced together in a third PCR. The oligonucleotide primers used to generate these fragments were MEGRT-1 and HHP1 or MEGRT-2 and HHP3. The sequences of oligonucleotide primers MEGRT-1 and MEGRT-2 were 5¢-
and 5¢-C CC C G T T A A T A A T C C T C A C C C C T C-3¢ respectively. The nucleotide integrity of all clones was confirmed by automated sequencing using an Applied Biosystems 377 sequencer.
The pCB6-Egr1 expression vector, encoding rat Egr1, and the backbone pCB6+ were kind gifts of Dr Egr1 or Sp1 (Santa Cruz Biotechnology, CA) following the protocol described previously (36).
Chemiluminescence was detected using ECL Western Blotting detection Reagents (Amersham Biosciences, UK).
RNA extraction and real time quantitative RT-PCR-Total RNA was extracted from
Jurkat T cells (1 x 10 6 cells) that were unstimulated or stimulated with 20 ng/ml PMA and 1mM IO, using Trizol (Invitrogen, Carlsbad, CA) as described by the manufacturer. 1 mg of total RNA was used for cDNA synthesis using a first strand cDNA synthesis Kit as per the manufacturer's instructions (Amersham Biosciences, England). SYBR Green (Qiagen) real-time PCR reactions were performed using a ABI PRISM 7700 sequence detector (PerkinElmer, Shelton, CO) in a total volume of 20 ml after each experiment to confirm a single product was amplified. A standard curve was generated for both HPSE and Egr1 using known copy numbers of a plasmid containing the cDNA specific to the gene. This standard curve was then used to convert the Ct value of the sample to copy number of
mRNA. An aliquot of each sample was also analysed using the same method to detect Ubiquitinconjugating enzyme E2D 2 (UBC) copy number. This was used for the normalisation for variations in RNA input and cDNA synthesis, as the expression of UBC mRNA was determined to remain 
Nuclear Extraction and Electrophoretic Mobility Shift Assay (EMSA)-
Jurkat T cells previously stimulated with 20 ng/ml PMA, 1 mM IO or both, were harvested and washed in 1ml ice-cold PBS. Nuclear extraction was then performed as previously described (37 
Induction of active EAE and immunohistochemistry-Lewis rats were immunised with 25
mg MBP (myelin basic protein) in FCA containing 4 mg/ml Mycobacterium butyricum as described previously (39) . At the clinical stage of EAE, lumbar spinal cords were fixed in 4% paraformaldehyde.
Following antigen retrieval with citrate buffer pH 6.0, 4 mm serial sections were stained for HPSE, Egr1,
or assessed for non-specific binding, using rabbit polyclonal antibodies against rat HPSE (generous gift of lines (11, 34) . Four fragments of the promoter region, described relative to the transcription start site i.e.
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HPSE expression is induced by PMA and IO-
-1281/+118 (1300 bp), -391/+118 (520 bp), -164/+118 (280 bp) and +3/+118 (120 bp) ( 
Mutation of the Egr1 core sequence ablates luciferase promoter activity-
Sequence analysis of the -164 bp to +2 bp HPSE promoter region using MatInspector (41) 78% compared to the wild-type (Fig. 3) . In addition, 95% of basal expression was also lost by the transversion mutant. These results indicate that the GGCG motif is critical to transcriptional regulation of the HPSE gene in Jurkat T cells, and suggest that Egr1 may play an important role.
Egr1 binds the HPSE promoter-Electrophoretic shift analysis was performed to determine whether Egr1 was able to bind to the element identified above. Firstly, we established whether was most apparent at 3 hours post-stimulation (Fig. 4A) . Interestingly, this complex was still detectable at 8 hours after stimulation. The specificity of the complex was confirmed by its supershift using an antiEgr1 antibody (Fig. 4A Lane 6 ). The intensity of these DNA-protein complexes corresponded with the level of protein expression of Egr1 in nuclear extracts as detected by Western blotting (Fig. 5B) confirming it is dependent on the availability of Egr1 protein in the nucleus. The complex labelled C1 is Sp1 (data not shown), and the complex labelled C2 is as yet unidentified.
These studies were then extended to examine the interaction between the HPSE promoter oligonucleotide (hep) 5'-GAGGGGTGAGGAGGCGTAACGGGGCGGAGG-3' that encompassed the putative Egr1 binding site (underlined), with nuclear extracts from Jurkat T cells either unstimulated or stimulated with PMA/IO for 3 hours. An inducible specific nucleoprotein complex formed with the labelled probe (Fig. 4B ) which was confirmed to contain Egr1 by supershift (Fig. 4B, lane 4) . This supershift was absent when the nuclear extract was pre-incubated with the non-specific antibody, YY1
( expected, neither inhibitor showed a significant effect on the truncated construct pXP-1/120bp (Fig. 6B ).
These data suggest that inducible HPSE transcription is mostly dependent on the MEK pathway, but the p38 MAPK pathway may play a minor role.
Real time quantitative RT-PCR was then used to assess the effect of these inhibitors at the level of HPSE and Egr1 gene expression. HPSE mRNA was inhibited significantly by 30 mM PD98059 (52%) but minimally by 1 mM SB202190 (14%) (Fig. 6C ). The level of inhibition resulting from pre-exposure of cells to both 30 mM PD98059 and 1 mM SB202190 (47%) was similar to that seen with PD98059 alone suggesting there is no cooperative mechanism regulating HPSE expression when both inhibitors are used (Fig. 6C ). This observation is consistent with the inhibition of inducible transcription of the 280 bp HPSE promoter region seen with both PD98059 and SB202190 and again suggests that the MEK pathway plays a major role in HPSE expression.
Egr1 expression at the level of mRNA and protein was assessed under the same stimulation conditions to confirm the pathways required for its expression in Jurkat T cells. Egr1 mRNA was inhibited significantly by 30 mM PD98059 (60%) but minimally by 1 mM SB202190 (8%) (Fig. 6C) .
Again, the level of inhibition resulting from pre-exposure of cells with both 30 mM PD98059 and 1 mM SB202190 was similar to that seen with PD98059 alone. The effect of the inhibitors PD98059 and SB202190 on Egr1 protein expression was assessed by Western blot analysis of Jurkat T cells stimulated with PMA and IO. Egr1 inducible expression in nuclear extracts was inhibited by 30 mM PD98059 but not by 1 mM SB202190 (Fig. 6D) . This is consistent with the expression of Egr1 seen at the level of mRNA level (Fig. 6C ). Sp1 expression was included as a loading control (Fig. 6D ). These data confirm Egr1 expression is regulated by the MEK pathway, a finding that is consistent with experiments carried out on other cell types. 
DISCUSSION
HPSE is a normal constituent of leukocytes where it has been implicated in promoting cell migration to sites of inflammation (27) . The regulation of HPSE expression and activity in leukocytes obviously needs to be tightly controlled to prevent erroneous HS degradation that can result in tissue damage. As such, HPSE activity is generally associated with leukocytes only in their activated states. This has been best characterized in T cells, which have high levels of HPSE activity when activated but not in their resting state (27) . The elevated levels of HPSE activity in activated T cells has been associated with autoimmune disorders such as rheumatoid arthritis (RA) (42) and experimental autoimmune encephalomyelitis (EAE) (10) . Indeed, inhibition of HPSE has been shown to decrease the severity of these diseases (10) . Furthermore, high levels of HPSE activity is also induced upon activation of certain non-hematopoietic cells such as endothelial cells and smooth muscle cells (21, 43, 44) , again reflecting the importance of tightly controlling HPSE function. Similarly, the erroneous expression of HPSE by these cell types has been linked with restenosis and atherosclerotic disease (45) . Recent studies in tumour cells have demonstrated that elevated levels of HSPE protein, observed in highly invasive/metastatic tumors, correlates directly with increased levels of HPSE mRNA (13, 14) . This suggests that the control of HPSE expression at the transcriptional level is important in regulating HPSE function. The molecular basis of HPSE gene transcription is poorly understood, and nothing is known of the mechanisms that lead to inducible transcription. In this study, using the Jurkat T cell line as a model, we have demonstrated that HPSE gene transcription is induced upon activation and have identified an inducible cis-acting element in the HPSE promoter. Additionally, we have shown that the transcription factor Egr1 can specifically bind to this site and induce HPSE transcription upon cell activation. This is the first description of the transcriptional mechanisms underlying inducible regulation of the HPSE gene.
Egr1 is a serum-inducible zinc finger transcription factor also known as knox24, zif268 or NGFI-A (46, 47) . It has been well characterised as a key transcription factor induced upon activation of smooth muscle cells (48) and endothelial cells (46) . We have shown that Egr-1 is also induced in T cells upon activation with PMA and IO. The role of Egr1 in T cells is less well defined, however it has been suggested to act as a regulator of Fas ligand expression (49) and thymocyte development (50) .
Significantly, the Egr1 promoter is activated by TCR agonist ligands (51) We have shown this region binds Egr1 and propose that it also binds Sp1 in our T cell model. In support of this, the C3 complex observed in our EMSA studies in un-stimulated cell nuclear extracts is likely to be Sp1 as; (i) it has been previously shown that Sp1 binds to this sequence of the HPSE promoter in thyroid tumour cells (34), (ii) the C3 complex is lost when the GGCG motif is mutated, and (iii), previous studies using a consensus Egr1 binding oligonucleotide in EMSA have identified a C1 complex which contains Sp1 (37) , and this complex exhibits a similar electrophoretic mobility to the C3 complex promoter, located at -700 to -3500 bb and -598 to -1089 bp, respectively. These regions are upstream of that identified herein, however the previous studies were performed in thyroid or breast tumour cell lines, and could therefore reflect differences in HPSE gene regulation between these cells and leukocytes.
Sequence analysis of the -391 to -164 bp region of the HPSE promoter has revealed several potential binding sites for transcription factors with repressor activities, including Ikaros and c-myc. The role of these sites in regulating HPSE transcription is currently being investigated.
Activation of T lymphocytes triggers several signalling cascades, including the MAP kinase pathways that transduce messages from the cell membrane to the nucleus. We used inhibitors to specific MAP kinase pathways to determine those that may control induction of HPSE and Egr1 expression in T cells. PD98059 is an inhibitor that binds inactive MEK and prevents phosphorylation of Raf, resulting in specific blocking of PMA induction of the ERK1/2 (MEK1/2) pathway. Our transient transfection studies of the HPSE promoter using PD98059 have shown inducible HPSE transcription to be dependent on this pathway. We then went on to show induction of Egr1 mRNA and protein in Jurkat T cells to be dependent on the ERK 1/2 pathway, a finding consistent with previous studies carried out in other cell types (55) . Although the ERK1/2 pathway regulates several other nuclear proteins (56), when these inhibitor results are put into the context of co-transfection and mutation studies carried out on the HPSE promoter, they are highly suggestive that the ERK1/2 pathway regulates HPSE expression through its regulation of Egr1.
The proposed importance of Egr1 in regulating inducible HPSE transcription in T cells implies that
Egr1 is likely to have a role in T cell mediated inflammatory disease in which elevated HPSE expression has been associated. Indeed, analysis of the expression of HPSE and Egr1 by immunohistochemistry in tissues sections of active EAE as described in this study, have demonstrated that HPSE and Egr1 are coexpressed by the invading mononuclear leukocytes responsible for mediating the inflammatory response. These studies provide the first insight into inducible regulation of HPSE at the level of transcription.
It is possible that these regulatory mechanisms are not cell restricted to T cells but may also occur across a variety of cells in which HPSE expression is induced. As discussed, HPSE expression is inducible in non-hematopoietic cells such as endothelial cells and smooth muscle cells (21, 43, 44) . Egr1 expression is well characterized in these cell types (46, 48) where it tightly regulates inducible expression of a number of genes including PDGF-A and B, tissue factor, transforming growth factor-b and MT1-MMP (46, 57) .
However, it is interesting to note that the vascular endothelial cells in vessels of the EAE sections described in this study were found to express HPSE but not Egr1. This implies that HPSE expression in endothelial cells may, in fact, be regulated by a different mechanism. Furthermore, while studies of the role of Egr1 in tumour cell metastasis and angiogenesis are contradictory, there have been several studies which correlate Egr1 expression with prostate tumour malignancy (58, 59) . As the over-expression of HPSE in various invasive tumours is strongly suggested to be a result of increased transcription, it would be of significant interest to determine if Egr1 is a key factor contributing to the high level of HPSE expression in metastatic tumour cells. 
